![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-naïve, genotype 1, mono-infected patients
|
|
|
Reported by Jules Levin
HepDART - December 6, 2011
T Tanwandee1, C Luscombe2, C Achenbach3, G Ewart2, M Miller2 , J Wilkinson2 and R Murphy3 1 Siriraj Hospital, Thailand; 2Biotron Limited, Australia;3 Northwestern University USA
![hepDart1.gif](../images/120811/120811-1/hepDart1.gif)
![hepDart2.gif](../images/120811/120811-1/hepDart2.gif)
![hepDart3.gif](../images/120811/120811-1/hepDart3.gif)
![hepDart4.gif](../images/120811/120811-1/hepDart4.gif)
![hepDart5.gif](../images/120811/120811-1/hepDart5.gif)
![hepDart6.gif](../images/120811/120811-1/hepDart6.gif)
![hepDart7.gif](../images/120811/120811-1/hepDart7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|